Studies have revealed that metformin may activate the LKB1/AMPK signal pathway, inhibit protein synthesis, and induce cell cycle arrest and/or cell apoptosis, as well as eradicate cancer stem cells [3], thereby potentially reducing the cancer risk and BCR after the treatment of prostate cancer. This evidence concerns the gene STK11 and prostate carcinoma.